Skip to main navigation Skip to search Skip to main content

Dual aromatase-steroid sulfatase inhibitors

  • L. W. Lawrence Woo
  • , Christian Bubert
  • , Oliver B. Sutcliffe
  • , Andrew Smith
  • , Surinder K. Chander
  • , Mary F. Mahon
  • , Atul Purohit
  • , Michael J. Reed
  • , Barry V. L. Potter

Research output: Contribution to journal › Article › peer-review

90   Link opens in a new tab Citations (SciVal)

Abstract

By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.
Original languageEnglish
Pages (from-to)3540-3560
JournalJournal of Medicinal Chemistry
Volume50
Issue number15
DOIs
Publication statusPublished - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Dual aromatase-steroid sulfatase inhibitors'. Together they form a unique fingerprint.

Cite this